LDS/Medical Tests/Treponema pallidum Antibody, FTA-ABS, IgG, IgM

Treponema pallidum Antibody, FTA-ABS, IgG, IgM

Syphilis is a sexually transmitted infection (STI) caused by the bacterial spirochete Treponema pallidum. Syphilis can be divided into three infectious stages: primary, secondary, and early latent, and two non-infectious disease stages: late latent and tertiary.  Since Treponema can not be grown in culture, serologic testing is extremely important for accurate diagnosis.

During infection, a broad immune response is produced that consists of anti-treponemal and non-specific (cardiolipin) antibodies. Until fairly recently, serologic testing for syphilis involved non-specific screening tests such as Rapid Plasma Reagin (RPR) and Venereal Disease Research Laboratory (VDRL) tests. If one of the screening tests was positive, confirmation was required using a specific test such as FTA-ABS or MHA-TP.  Both of these tests are subjective and time consuming.  Advances in technology have allowed the introduction of treponema-specific antibody based tests for syphilis including enzyme immunoassay (EIA), chemiluminescent immunoassay (CLIA) and multiplex flow immunoassay (MFI), which can detect specific IgM and IgG treponema antibody.  These tests are highly sensitive, specific and objective.  Although the CDC still recommends syphilis screening using non-treponemal tests initially (VDRL or RPR), some laboratories have begun using treponemal-specific tests (EIA, CLIA, MFI) as the screening test with confirmation using non-treponemla tests (VDRL or RPR), so-called reverse sequence screening.  During primary syphilis, treponemal IgM may be detected within approximately two weeks post-infection and IgG about four weeks post-infection. Antibodies can usually be detected by the time clinical symptoms appear.  Of note is that treponemal antibodies appear before non-treponemal antibodies, and this can lead to negative confirmatory testing if the reverse sequence screening method is used for confirmatory testing, since the confirmatory tests in this reverse sequence are non-treponemal.  Also, false-positives can occur with treponema-specific tests (EIA, CLIA or MFI), especially in low-prevalence populations (when using FTA-ABS or TP-PA as the gold standard confirmatory tests).

Untreated syphilis during pregnancy can lead to miscarriage, premature or stillbirth, and birth defects. Testing of the mother is very important during the early stages of pregnancy so that treatment can be administered and the fetus can remain unaffected. It is estimated that approximately 12 million new cases of venereal syphilis occur each year worldwide (36,000 new cases in the U.S. in 2006).

  • Antibody screening for active T. pallidum infection
  • Differential diagnosis of syphilis infection
  • Immune status or past infection to T. pallidum infection
  • Prenatal screening
Non-Treponemal Ab Treponemal Ab Result Interpretation
Non-Reactive Non-Reactive No infection with T. pallidum (no syphilis infection)
Reactive Non-Reactive Might indicate current infection; may also represent a false positive — confirm with FTA or PCR
Non-Reactive Reactive Probable past infection or false positive; reflex to non-treponemal assay, and if reactive confirm with FTA or PCR
Reactive Reactive Current infection; requires confirmation with FTA or PCR

 

Negative (Non-reactive) or <0.9 index value

 

 

Chemiluminescent immunoassay (CLIA), Multiplex flow immunoassay (MFI), Enzyme immunoassay (EIA).

Serum (SST) or plasma (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days

RPR, VRDL, T. pallidum by DFA, T. pallidum by PCR, Treponema pallidum - Particulate aggregation (TP-PA), Microhemagglutinin assay (MHA-TP), Fluorescent treponemal-antibody absorbed (FTA-ABS), Anti-phospholipid antibody, HIV-1 and HIV-2 antibody screen, CBC with differential.

1-3 days. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Sex Transm Dis. 1998;25:569. [PMID: 9858355]
  • Int J STD AIDS. 1995 Jul-Aug;6(4):241-8. [PMID: 7548285]
  • J Emerg Med. 2000;18:361. [PMID: 10729677]
  • Dermatol Clin. 2006;24:497. [PMID: 17010778]
  • Morbidity and Mortality Weekly Report, Feb 11, 2011 / 60(05); 133-137.
  • Stevens CD. Clinical Immunology & Serology A Laboratory Perspective* 3rd edition. Philadelphia: F.A. Davis Company (2010).